BioAge Labs (BIOA) FCF Margin (2025 - 2026)
BioAge Labs (BIOA) posted FCF Margin of 868.4% for Q1 2026, up 5.76% sequentially from 921.47% in Q4 2025, and up 35758.0% YoY from N/an in Q1 2025.
BioAge Labs (BIOA) FCF Margin (2025 - 2026) Analysis & Trends
BioAge Labs has reported FCF Margin for 2 years, with the latest figure at 868.4% in Q1 2026.
- Quarterly FCF Margin rose 35758.0% year-over-year to 868.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 859.14% (up 285409.0% YoY) and the FY2025 annual result came in at 915.46%, changed N/A from the prior year.
- FCF Margin grew to 868.4% in Q1 2026 per BIOA's latest filing, from 921.47% in the prior quarter.
- Over five years, FCF Margin peaked at 782.18% in Q3 2025 and troughed at 1225.98% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioAge Labs | 434.04 Mn | 434.04 Mn | -14.23 Mn | -799.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -799.18% |
| Mar 31, 2026 | -868.40% |
| Dec 31, 2025 | -921.47% |
| Sep 30, 2025 | -782.18% |
| Jun 30, 2025 | -834.49% |
| Mar 31, 2025 | -1,225.98% |